Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook, PMID: 32335505
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding, PMID: 28882537
The role of bevacizumab in the treatment of glioblastoma, PMID: 28527008
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars, PMID: 28801849
Bevacizumab in advanced lung cancer: state of the art, PMID: 28812378
Bevacizumab in ovarian cancer: A critical review of phase III studies, PMID: 27852039
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial, PMID: 28481967
Bevacizumab in Cervical Cancer: 5 Years After, PMID: 30119082
The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review, PMID: 29710531
[Bevacizumab], PMID: 30634827
Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity, PMID: 29223789
Bevacizumab treatment of meningeal melanoma metastases, PMID: 31915016
The use of bevacizumab in pediatric retinal and choroidal disease: A review, PMID: 30757919
Introduction by the Guest Editors: Bevacizumab, PMID: 30119078
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma, PMID: 32564774
[Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer], PMID: 32702797
Commentary: Single-use bevacizumab: The final solution?, PMID: 32461440
Systemic bevacizumab for recurrent respiratory papillomatosis, PMID: 32906078
Perforating folliculitis triggered by bevacizumab administration, PMID: 32463526
Vascular effect of bevacizumab: is it too early to draw conclusions?, PMID: 31913945
Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature, PMID: 29580267
Critical appraisal of bevacizumab in the treatment of ovarian cancer, PMID: 25960638
Monitoring antiangiogenesis of bevacizumab in zebrafish, PMID: 30122900
Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer, PMID: 32272489
Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer, PMID: 30663563
Off-label infusion of biosimilar bevacizumab: A provincial experience, PMID: 32727322
Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults, PMID: 32249894
Use of bevacizumab in recurrent glioblastoma, PMID: 25906439
Systemic Bevacizumab (Avastin) for Juvenile-Onset Recurrent Respiratory Papillomatosis: A Systematic Review, PMID: 32959914
Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer, PMID: 29526256
The role of selenium in bevacizumab induced cardiotoxicity, PMID: 30793617
In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer, PMID: 32040774
Microneedle-Mediated Transdermal Delivery of Bevacizumab, PMID: 29996645
Impaired wound healing secondary to bevacizumab, PMID: 31111622
Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy, PMID: 32753135
[Application of Bevacizumab in Non-small Cell Lung Cancer], PMID: 28442017
Bevacizumab: a new way of doing business. Part 2, PMID: 30482906
Practical management of bevacizumab-related toxicities in glioblastoma, PMID: 25568148
Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality, PMID: 33044752
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement, PMID: 33405268
Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent, PMID: 26651298
Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma, PMID: 30835573
The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, PMID: 27138763
The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer, PMID: 27748633
Clinical use of Bevacizumab in treating refractory glaucoma, PMID: 25914729
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice, PMID: 32052341
Gravity influences bevacizumab distribution in an undisturbed balanced salt solution in vitro, PMID: 31584989
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis, PMID: 31889159
[Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity], PMID: 25459682
Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial, PMID: 32502179
Efficacy and safety of combining re-irradiation with bevacizumab compared to bevacizumab alone in the management of recurrent high-grade gliomas: a meta-analysis and systematic review., PMID:40529988
Comment on: 'Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity'., PMID:40527930
An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics., PMID:40526406
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study., PMID:40525526
Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab., PMID:40522519
Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs., PMID:40522452
Survival Impact of Neoadjuvant Chemotherapy With Bevacizumab Followed by Radical Hysterectomy for Locally Advanced Cervical Cancer With Lymph Node Metastasis: Insights From a Single-Institution Experience., PMID:40520831
Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis., PMID:40520171
Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies., PMID:40518650
Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature., PMID:40518311
Physicochemical Stability of a Bevacizumab Biosimilar in Vials and Diluted Preparations: Implications for Hospital Practice and Inventory Management., PMID:40518070
Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF., PMID:40517351
Bevacizumab-Conjugated Curcumin Nanoparticles Promote Cytotoxicity and Apoptosis in Human Malignant Oral Keratinocytes In Vitro., PMID:40514017
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial., PMID:40513287
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas., PMID:40511882
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics., PMID:40508182
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study., PMID:40507295
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas., PMID:40506054
Advances in drug treatments for male patients with prolactinomas., PMID:40505642
The use of Bevacizumab in the treatment of brain arteriovenous malformations: a systematic review., PMID:40504282
Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations., PMID:40503036
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer., PMID:40501444
A Neovascularization and EGFR Dual-Targeting Gold Nanotheranostic System for Non-Small Cell Lung Cancer Treatment., PMID:40500941
Response to the comment on our manuscript "Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells"., PMID:40500641
Targeting the ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti-VEGF resistance in endometrial cancer., PMID:40497576
Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma., PMID:40497086
Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing., PMID:40496606
Bevacizumab in recurrent epithelial ovarian cancer: real-world experience from a tertiary cancer hospital in India., PMID:40496305
Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study., PMID:40495727
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population., PMID:40494131
Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab., PMID:40493293
Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children's Hospital experience., PMID:40487589
Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma., PMID:40486515
Response to 'Comment on: 'Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity"., PMID:40483306
Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial., PMID:40483175
Multimodal nanoparticles co-delivering bevacizumab and dichloroacetate for dual targeting of neoangiogenesis and hyperglycolysis in glioblastoma treatment., PMID:40482922
Revisiting the Role of Intravitreal Triamcinolone in Diabetic Macular Edema: 12-Month Outcomes after Bevacizumab Failure., PMID:40481980
Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective., PMID:40481910
Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma., PMID:40481877
Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study., PMID:40481786
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma., PMID:40479621
A case report of small cell neuroendocrine carcinoma of the ovary and review of the literature., PMID:40475766
Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies., PMID:40474872
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial., PMID:40473448
Clinical characteristics and treatment response of treatment requiring retinopathy of prematurity (ROP) in Big Premature Infants in Turkiye: BIG-ROP Study Group Report No 2 (BIG-ROP STUDY)., PMID:40473274
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study., PMID:40472923
Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact., PMID:40471504
For research use only. Not for human or drug use.
